Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03599726 · ClinicalTrials.gov registry record · Early Phase 1
Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil
A Early Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT03599726 is a Early Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 20 participants.
The verdict
NCT03599726, a Early Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Safe and independent mobility at home and in the community requires control of walking while accomplishing other functional tasks. A hallmark of healthy control of walking is automaticity, defined as the ability of the nervous system to successfully coordinate movement with minimal use of attention-demanding executive resources \[1\]. Recent evidence indicates that walking disorders are often characterized by a shift in the locomotor control strategy from healthy automaticity to compensatory executive control. This shift is potentially detrimental to walking performance as an executive control strategy is not optimized for locomotor control and it places excessive demands on a limited pool of cognitive reserve. Here, the investigators hypothesize that walking automaticity, as measured by the prefrontal cortex activity while walking, will be improved by donepezil (a cholinesterase inhibitor).
Interventions
- DRUG Placebo
- DRUG Donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2019-07-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03599726
The ClinicalTrials.gov registry entry for NCT03599726 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03599726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03599726 about?
NCT03599726 is a clinical study titled "Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil". Safe and independent mobility at home and in the community requires control of walking while accomplishing other functional tasks. A hallmark of healthy control of walking is automaticity, defined as the ability of the nervous system to successfully coordinate movement with minimal use of attention-...
What is the current status of trial NCT03599726?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2018-07-30. Estimated completion is 2019-07-30.
What interventions are being tested in trial NCT03599726?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG).
Who is sponsoring clinical trial NCT03599726?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.